Crucell CFO to present at two June Investor Conferences
Leiden, The Netherlands, June 6 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that Chief Financial Officer, Leonard Kruimer, will participate in two June investor conferences. On Tuesday, June 12, at 1.20 PM (PDT), Mr. Kruimer will present at the Goldman Sachs 28th Annual Global Healthcare Conference being held at the Ritz Carlton Hotel in Laguna Nigel, California. In addition, Mr. Kruimer will present at the Needham Sixth Annual Biotechnology & Medical Technology Conference being held at the New York Palace Hotel on Thursday, June 14 at 1:00 PM (EDT).
A live webcast of each presentation will be accessible through Crucell’s website at www.crucell.com. The webcast will also be available for replay afterwards. Both presentations will be archived for 90 days.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled “Risk Factors”. The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
- Contact Information
- Barbara Mulder
- Director Corporate Communications
- Crucell N.V.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.